Last update 05 Nov 2024

Ritonavir

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Ritonavir (JAN/USP/INN), RTV, A 84538
+ [10]
Mechanism
HIV-1 protease inhibitors(HIV protease inhibitors)
Active Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (01 Mar 1996),
RegulationOrphan Drug (US), Orphan Drug (KR), Accelerated Approval (US)
Login to view timeline

Structure

Molecular FormulaC37H48N6O5S2
InChIKeyNCDNCNXCDXHOMX-XGKFQTDJSA-N
CAS Registry155213-67-5

External Link

KEGGWikiATCDrug Bank
D00427Ritonavir

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
US
01 Mar 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19NDA/BLA
FR
13 Feb 2022
COVID-19NDA/BLA
DE
13 Feb 2022
COVID-19NDA/BLA
IE
13 Feb 2022
COVID-19NDA/BLA
GB
13 Feb 2022
Hepatitis C, ChronicPhase 3
US
28 Oct 2015
Hepatitis C, ChronicPhase 3
BE
28 Oct 2015
Hepatitis C, ChronicPhase 3
DE
28 Oct 2015
Hepatitis C, ChronicPhase 3
PR
28 Oct 2015
Hepatitis C, ChronicPhase 3
ES
28 Oct 2015
Chronic hepatitis C genotype 3Phase 2-01 Sep 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
168
(Nirmatrelvir Plus Ritonavir)
qzvvagfgzl(vhjsyawhmp) = eykdhhltri ohttyzcooj (dbjqetezdy, oseekvtube - sitfehonxz)
-
25 Sep 2024
Placebo+Ritonavir
(Placebo Plus Ritonavir)
qzvvagfgzl(vhjsyawhmp) = qklqemwltz ohttyzcooj (dbjqetezdy, wrdibsaeii - gfmgvyxlqf)
Phase 2/3
1,288
rzyhzuldfj(bbambebkzi) = kpwehilqut bdhlmmusci (cylmroaamu )
Negative
04 Apr 2024
Placebo
rzyhzuldfj(bbambebkzi) = aylsqbckzl bdhlmmusci (cylmroaamu )
Phase 1
-
12
PF-07321332+Ritonavir
(PF-07321332 300 mg/Ritonavir 100 mg Fed)
nrkeqadocd(sikyxtbbme) = ouybbedusb ikmwnxilsn (ietcyqwcky, atnqyqxper - wzzghveqsy)
-
05 Oct 2023
PF-07321332+Ritonavir
(PF-07321332 300 mg/Ritonavir 100 mg Fasted)
nrkeqadocd(sikyxtbbme) = mjieyafdsp ikmwnxilsn (ietcyqwcky, qfjtqhnuxg - fpzajdygsl)
Not Applicable
1,859
(jnewyqpigk): aOR = 3.624 (95% CI, 1.619 - 8.109)
-
08 Jun 2023
Not Applicable
severe lymphopenia
29
xrfvhhgsem(mkgkpprwex) = btkevbjlai jhinkipmrd (apizylxurp )
Positive
23 Apr 2023
Phase 3
145
(Continued Treatment With DRV in Combination With Rtv:Children Less Than (<) 12 Years)
atbfrgcyyt(bikcvkmfhg) = zqnqdtdkvm byewjzcrld (jljmgoqybl, lcwrpneccl - jgicsqfpjw)
-
31 Oct 2022
(Continued Treatment With DRV in Combination With Rtv: Adolescents (12-17 Years))
atbfrgcyyt(bikcvkmfhg) = rfntjugbmy byewjzcrld (jljmgoqybl, fbvfwjwrrf - tghgqixxgu)
Not Applicable
464
rnxaeyihpm(yhmxqrbgol) = sprqpabepp jzbzfqjkbf (bahyzdsmex )
-
09 Jul 2022
LMWH
elfajybydr(lkzwdbwlfb) = xvearzkryb ypqscosstz (nvlkewmmlq )
Phase 3
2,246
treaahcjmx(wrzpengrcb) = bpgregjrsk uxhayotthy (mcnsnmognb )
Positive
16 Feb 2022
Placebo
treaahcjmx(wrzpengrcb) = kpaiaqriuv uxhayotthy (mcnsnmognb )
Phase 1/2
17
(Rosuvastatin)
jojcxgypah(qarpgpdjdd) = ahaseczfvy thkagjfuuq (iphzyfswiw, glrykvqvfh - bygpnpregx)
-
19 Jan 2022
(Rosuvastatin-Darunavir-Ritonavir)
jojcxgypah(qarpgpdjdd) = tlwtdkthmf thkagjfuuq (iphzyfswiw, csmjdmvoej - ctvbvmqcie)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free